MedTrace Logo

Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

NCT05237713 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-05-06

No results posted yet for this study

Summary

Hematologic improvement of erythrocytes after 6 months of canakinumab treatment.

Conditions

Interventions

DRUG

Canakinumab Injection

Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years

Sponsors & Collaborators

Principal Investigators

  • Anne Sophie Kubasch, Dr. · University Leipzig

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-26
Primary Completion
2024-02-29
Completion
2024-02-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05237713 on ClinicalTrials.gov